Tonix Pharmaceuticals Holding Corp. Stock
Our community identified positive and negative aspects for Tonix Pharmaceuticals Holding Corp. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Tonix Pharmaceuticals Holding Corp. stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Tonix Pharmaceuticals Holding Corp. in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Tonix Pharmaceuticals Holding Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. | - | - | - | - | - | - | - |
| Heron Therapeutics Inc. | 0.770% | 4.787% | -31.800% | -66.034% | -38.106% | -50.644% | -94.659% |
| Evolus Inc | -1.160% | -11.458% | -6.077% | -68.807% | -37.615% | -55.844% | -65.313% |
| Sangamo Therapeutics Inc. | -22.980% | -30.535% | -41.893% | -64.349% | -38.736% | -86.757% | -97.993% |
Comments
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) had its "buy" rating re-affirmed by analysts at Alliance Global Partners.
Show more
Ratings data for TNXP provided by MarketBeat
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) had its "outperform" rating re-affirmed by analysts at Noble Financial. They now have a $70.00 price target on the stock.
Show more
Ratings data for TNXP provided by MarketBeat
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for TNXP provided by MarketBeat
